Nimbus transitions to clinical development, raises $43m
This article was originally published in Scrip
Executive Summary
Nimbus Therapeutics (formerly Nimbus Discovery) has changed its name and raised $43m in a series B financing round in order to evolve into a clinical-stage company focused on treatments for Non-alcoholic Steatohepatitis (NASH).